MedTrace Logo

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

NCT07075185 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-04-24

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.

Conditions

  • Multiple Myeloma in Relapse
  • Myeloma Multiple
  • Multiple Myeloma Progression
  • Neoplasms by Histologic Type
  • Neoplasm
  • Hemostatic Disorders
  • Vascular Disorder
  • Paraproteinemias
  • Blood Protein Disorders
  • Hematologic Disease and Disorders
  • Lymphoproliferative Disorders
  • Immunoproliferative Disorders
  • Immune System Disease
  • Gene Therapy

Interventions

DRUG

KLN-1010

Given at specified dose one time

Sponsors & Collaborators

  • Kelonia Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-16
Primary Completion
2027-03-31
Completion
2042-05-31
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07075185 on ClinicalTrials.gov